In vivo effects of cyclophosphamide on oncogene and suppressor gene expression in a 'follow up' study

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3593-3597

  Ember, István ^a   Kiss, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Cyclophosphamide; Cyclosporine; Gene expression; Oncogenes; Secondary tumors

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOGENS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; GENE EXPRESSION; GENES, MYC; GENES, P53; GENES, RAS; MALE; MICE; MICE, INBRED CBA; ONCOGENES; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, MESSENGER; SPLEEN; THYMUS GLAND; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030827422     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rosner F, Grunwald HW and Zarrabi HM: Cancer after the use of alkcylating and nonaLkylating cytotoxic agents in man. Cancer Surv 1: 599-612, 1982.
2. Boivin JF and Hutchinson GB: Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease. J Natl Cancer Inst 67: 751-760, 1981.
3. Deegh HJ, Sanders J, Martin P, Feter A, Neiman P, Singer J, Storb R, and Thomas ED: Secondary malignancies after marrow transplantation. Exp Hematol 12: 660-666, 1984.
4. Dedrick RL and Morrison PF: Carcinogenic potency of alkylating agents in rodents and humans. Cancer Research 52: 2467-2467, 1992.
5. Sanderson BJ and Shield AJ: Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutation Res 355: 41-57, 1996.
6. Ryffel B: The carcinogenicity of ciclosporin. Toxicology 73: 1-22, 1992.
7. Ember I, Raposa T, Varga Cs, Herceg L, Kiss I: Carcinogenic effects of cytostatic protocols in CBA/Ca mice. In Vivo 9: 65-70, 1995.
8. Varga Cs, Ember I and Raposa T: Comparative studies on genotoxic and carcinogenic effects of different cytoststic protocols. I. In vivo cytogenetic analyses in CBA mice. Cancer Letters 60: 199-203, 1991.
9. Maniatis T, Fritsch EF and Sambrook J: Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory. 1982.
10. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid vuanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
11. Varmus HE: The molecular genetics of cellular oncogenes. Annu. Rev. Genet 18: 553-612, 1984.
12. Wynford-Thomas D: Oncogenes and anti-oncogenes; the molecular basis of tumor behaviour. J. Pathol 165: 187-201, 1991.
13. Beer DG and Pilot HG: Proto-oncogene activation during chemically induced hepatocarcinogenesis in rodents. Mutation Res 220: 1-10, 1989.
14. Masahura M, Ogasawara H, Katyal SL: Cyclosporine stimulates hepatocyte proliferation and accelerates development of hepatocellular carcinomas in rats. Carcinogenesis 14: 1579-1584, 1993.
15. Ember I, Kiss I, Dezsenyi E, Kertai P: Early effects of cyclosporin A on in vivo oncogene expression. Anticancer Res 14: 1095-96, 1994.
16. Evans R, Kamdar SJ and Duffy TM: Qualitative and quantitative intratumoral changes in gene expression following cyclophosphamide injection and the adoptive transfer of T cells: the potential contribution of tumor-associated macrophages. Int J Cancer 56: 568-573, 1994.
17. Brook-Kaiser JC, Borque LA and Hoskin DW: Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology 25: 117-129, 1993.
18. McClure MT and Stupans I: Hormonal perturbation as a possible mechanism for the alteration of cytochrome P450 by cyclophosphamide. Biochem-Pharmacol 49: 1827-1836, 1995.
19. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD and Idle JR: Cyclophosphamide metabolism in children. Cancer Res 55: 803-809, 1995.